The dust from the 2022 Midterm Elections has settled and the 118th Congress has begun. Republicans were successfully able to flip control of the House and now have a 222-212 majority with one vacancy to be filled. Democratic...more
1/18/2023
/ Child Tax Credit ,
Climate Change ,
Communications Decency Act ,
Congressional Review Act ,
Consolidated Appropriations Act (CAA) ,
Department of Energy (DOE) ,
Environmental Protection Agency (EPA) ,
Food and Drug Administration (FDA) ,
General Elections ,
Healthcare ,
Inflation Reduction Act (IRA) ,
Infrastructure ,
Infrastructure Investment and Jobs Act (IIJA) ,
Medicare ,
Pharmacy Benefit Manager (PBM) ,
Popular ,
Rapanos v US ,
SALT ,
State Elections ,
Tax Cuts and Jobs Act ,
US Army Corps of Engineers ,
Waters of the United States
As September gets underway and Washington returns from a busy recess, important deadlines loom. August saw the introduction and passage of the Inflation Reduction Act, the Biden Administration’s announcement of student debt...more
Foley’s Bipartisan Public Policy Team is pleased to share our Public Policy August Recess Health Care Newsletter in which we compiled the top health care policy news and legislation from this month. The House was not in...more
8/28/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Prescription Drugs
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/24/2018
/ Appropriations Bill ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Budget ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Legislative Committees ,
Medicaid ,
Medicare ,
Medicare Access and CHIP Reauthorization (MACRA) ,
Opioid ,
Secretary of HHS ,
Stark Law ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
7/2/2018
/ Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Fraud ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
New Legislation ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Section 340B ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration ,
Veterans Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration